Paysign Targets $117M Revenue as Patient-Affordability Business Surges
Paysign NASDAQ: PAYS operates in two healthcare-focused businesses: payment services for plasma donors and pharmaceutical patient-affordability programs, Chief Financial Officer Jeff Baker said during a company presentation.
Paysign (PAYS) is an Incredible Growth Stock: 3 Reasons Why
Paysign (PAYS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Paysign (PAYS) Upgraded to Buy: What Does It Mean for the Stock?
Paysign (PAYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Business Services Stocks Lagging Paysign (PAYS) This Year?
Here is how Paysign, Inc. (PAYS) and Sezzle Inc. (SEZL) have performed compared to their sector so far this year.
3 Reasons Growth Investors Will Love Paysign (PAYS)
Paysign (PAYS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Paysign Q2 Earnings Call Highlights
Paysign NASDAQ: PAYS reported record second-quarter revenue, net income and adjusted EBITDA for 2026, driven primarily by continued expansion in its Patient Affordability business and improving utilization in its plasma donor compensation operations.
Paysign, Inc. (PAYS) Q2 2026 Earnings Call Transcript
Paysign, Inc. (PAYS) Q2 2026 Earnings Call Transcript
Paysign, Inc. (PAYS) Q1 2026 Earnings Call Transcript
Paysign, Inc. (PAYS) Q1 2026 Earnings Call Transcript
Paysign Q1 Earnings Call Highlights
Paysign NASDAQ: PAYS reported what executives described as the strongest start to a year in the company's history, with first-quarter 2026 revenue rising 50.8% year over year to $28 million and profitability expanding sharply as its patient affordability business became its largest revenue contributor.
Paysign: The Market Is Finally Repricing A Pharma Margin Story
Paysign is evolving beyond a niche prepaid card processor, with patient affordability now driving higher-margin growth. 2025 results highlight a 40.5% revenue increase to $82M, with pharma revenue surging to $33.9M and gross margin expanding to 59.4%. PAYS trades above peer sales multiples, reflecting its shift to a high-value workflow business, while price-to-cash flow remains attractive if cash conversion holds.
Paysign Is On A Roll
Paysign remains a buy, supported by strong performance in both Plasma Centers and hypergrowth in Patient Affordability. PAYS's Plasma Center segment holds a 50% market share, adding 115 new centers in FY25, despite revenue per center declining due to plasma surplus. That surplus can disappear, and the Plasma segment can benefit from the BECS, generating high-margin SaaS subscription revenue.
Paysign, Inc. (PAYS) Q4 2025 Earnings Call Transcript
Paysign, Inc. (PAYS) Q4 2025 Earnings Call Transcript
